Forward Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Forward Therapeutics, Inc. - overview
Established
2022
Location
Palm Beach, FL, US
Primary Industry
Biotechnology
About
Established in 2022 and based in Florida, US, Forward Therapeutics, Inc. operates as a biotechnology company that offers clinical-stage gene therapy for patients with rare diseases. Toufike Kanouni (CEO) and Ewan Taylor (CSO) are the co-founders of the company. In October 2023, Forward Therapeutics, Inc.
raised USD 50 million in Series A funding from BVF Partners, including RA Capital Management and OrbiMed Advisors. The company specializes in the delivery of oral medications for chronic inflammatory disorders. The firm focuses on target selection based on verified immunological targets, discovering pathways that have the potential to influence patient outcomes. Forward Therapeutics also combines scientific knowledge with operational efficiencies to ensure drug development through integrated discovery and development.
The organization plans to use the October 2023 funding to advance the clinical development of its small-molecule immunology medications.
Current Investors
OrbiMed Advisors, BVF Partners, RA Capital Management
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy
Website
www.forward-tx.com
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.